S. Yadav, J. Mindur, K. Ito, and S. Dhib-jalbut, Advances in the immunopathogenesis of multiple sclerosis, Current Opinion in Neurology, vol.28, issue.3, pp.206-219, 2015.
DOI : 10.1097/WCO.0000000000000205

O. Finn, Immuno-oncology: understanding the function and dysfunction of the immune system in cancer, Annals of Oncology, vol.23, issue.suppl 8, pp.6-9, 2012.
DOI : 10.1093/annonc/mds256

S. Bahmanyar, S. Montgomery, J. Hillert, A. Ekbom, and T. Olsson, Cancer risk among patients with multiple sclerosis and their parents, Neurology, vol.72, issue.13, pp.1170-1177, 2009.
DOI : 10.1212/01.wnl.0000345366.10455.62

C. Lebrun, P. Vermersch, D. Brassat, G. Defer, L. Rumbach et al., Cancer and multiple sclerosis in the era of disease-modifying treatments, Journal of Neurology, vol.8, issue.6, pp.1304-1311, 2011.
DOI : 10.2165/00128071-200708060-00002
URL : https://hal.archives-ouvertes.fr/hal-00996630

M. Buttmann, L. Seuffert, U. Mäder, and K. Toyka, Malignancies after mitoxantrone for multiple sclerosis, Neurology, vol.86, issue.23, p.27170571, 2016.
DOI : 10.1212/WNL.0000000000002745
URL : http://www.neurology.org/content/86/23/2203.full.pdf

R. Marrie, N. Reider, J. Cohen, O. Stuve, M. Trojano et al., A systematic review of the incidence and prevalence of cancer in multiple sclerosis, Multiple Sclerosis Journal, vol.8, issue.3, pp.294-304, 2015.
DOI : 10.1186/1756-8722-5-59

A. Fois, C. Wotton, D. Yeates, M. Turner, and M. Goldacre, Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies, Journal of Neurology, Neurosurgery & Psychiatry, vol.81, issue.2, pp.215-221, 2010.
DOI : 10.1136/jnnp.2009.175463

C. Confavreux, D. Compston, O. Hommes, W. Mcdonald, and A. Thompson, EDMUS, a European database for multiple sclerosis., Journal of Neurology, Neurosurgery & Psychiatry, vol.55, issue.8, pp.671-676, 1992.
DOI : 10.1136/jnnp.55.8.671
URL : http://jnnp.bmj.com/content/jnnp/55/8/671.full.pdf

D. Machin, M. Campbell, S. Tan, and S. Tan, Sample Size Tables for Clinical Studies, 2011.
DOI : 10.1002/9781444300710

P. Austin, An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies, Multivariate Behavioral Research, vol.110, issue.3, pp.399-424, 2011.
DOI : 10.1016/j.drugalcdep.2009.03.018

P. Austin, The Relative Ability of Different Propensity Score Methods to Balance Measured Covariates Between Treated and Untreated Subjects in Observational Studies, Medical Decision Making, vol.39, issue.6, pp.661-677, 2009.
DOI : 10.1002/sim.2053

P. Austin and D. Small, The use of bootstrapping when using propensity-score matching without replacement: a simulation study, Statistics in Medicine, vol.99, issue.467, pp.4306-4319, 2014.
DOI : 10.1198/016214504000000647

P. Austin, Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples, Statistics in Medicine, vol.17, issue.1, pp.3083-3107, 2009.
DOI : 10.1007/978-1-4757-3462-1

E. Kingwell, C. Bajdik, N. Phillips, F. Zhu, J. Oger et al., Cancer risk in multiple sclerosis: findings from British Columbia, Canada, Brain, vol.135, issue.10, pp.2973-2979, 2012.
DOI : 10.1093/brain/aws148

C. Lebrun, M. Debouverie, P. Vermersch, P. Clavelou, L. Rumbach et al., Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis, Multiple Sclerosis Journal, vol.23, issue.5, pp.399-405, 2008.
DOI : 10.1159/000079947
URL : https://hal.archives-ouvertes.fr/hal-00492565

E. Kingwell, C. Evans, F. Zhu, J. Oger, S. Hashimoto et al., Assessment of cancer risk with ??-interferon treatment for multiple sclerosis, Journal of Neurology, Neurosurgery & Psychiatry, vol.59, issue.(Suppl 1), pp.1096-1102, 2014.
DOI : 10.1212/01.WNL.0000034080.43681.DA

L. Bouc, R. Zéphir, H. Majed, B. Vérier, A. Marcel et al., No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis, Multiple Sclerosis Journal, vol.42, issue.1, pp.55-63, 2012.
DOI : 10.1177/1352458508100967

P. Monach, L. Arnold, and P. Merkel, Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review, Arthritis & Rheumatism, vol.42, issue.6, pp.9-21, 2010.
DOI : 10.1038/bjc.1984.252

X. Mariette, D. Cazals-hatem, J. Warszawki, F. Liote, N. Balandraud et al., Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France, Blood, vol.99, issue.11, pp.3909-3915, 2002.
DOI : 10.1182/blood.V99.11.3909

J. Swann and M. Smyth, Immune surveillance of tumors, Journal of Clinical Investigation, vol.117, issue.5, pp.1137-1146, 2007.
DOI : 10.1172/JCI31405

M. Vesely, M. Kershaw, R. Schreiber, and M. Smyth, Natural Innate and Adaptive Immunity to Cancer, Annual Review of Immunology, vol.29, issue.1, pp.235-271, 2011.
DOI : 10.1146/annurev-immunol-031210-101324

X. Xie, Y. Zhao, C. Ma, X. Xu, Y. Zhang et al., Dimethyl fumarate induces necroptosis in colon cancer cells through glutathione depletion/ROS increase/MAPKs activation pathway, Br J Pharmacol, vol.https, p.25953698, 2015.

C. White, H. Alshaker, C. Cooper, M. Winkler, and D. Pchejetski, The emerging role of FTY720 (Fingolimod) in cancer treatment, Oncotarget, vol.7, issue.17, p.27036015, 2016.
DOI : 10.18632/oncotarget.7145

O. Huang, W. Zhang, Q. Zhi, X. Xue, H. Liu et al., Featured Article: Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells, Experimental Biology and Medicine, vol.60, issue.4, pp.426-437, 2015.
DOI : 10.1158/2159-8290.CD-13-0041
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935377/pdf